uAUG creating variants in the 5'UTR of ENG causing Hereditary Hemorrhagic Telangiectasia.
Journal
NPJ genomic medicine
ISSN: 2056-7944
Titre abrégé: NPJ Genom Med
Pays: England
ID NLM: 101685193
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
received:
27
02
2023
accepted:
03
10
2023
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
Hereditary Hemorrhagic Telangiectasia (HHT) is a rare, autosomal dominant, vascular disorder. About 80% of cases are caused by pathogenic variants in ACVRL1 (also known as ALK1) and ENG, with the remaining cases being unexplained. We identified two variants, c.-79C>T and c.-68G>A, in the 5'UTR of ENG in two unrelated patients. They create upstream AUGs at the origin of upstream overlapping open reading frames (uoORFs) ending at the same stop codon. To assess the pathogenicity of these variants, we performed functional assays based on the expression of wild-type and mutant constructs in human cells and evaluated their effect on ALK1 activity in a BMP-response element assay. This assay is mandatory for molecular diagnosis and has been so far only applied to coding ENG variants. These variants were associated with a decrease of protein levels in HeLa and HUVEC cells and a decreased ability to activate ALK1. We applied the same experiments on three additional uoORF-creating variants (c.-142A>T, c.-127C>T and c.-10C>T) located in the 5'UTR of ENG and previously reported in HHT patients. We found that all the analyzed variants alter protein levels and function. Additional experiments relying on an artificial deletion in our mutated constructs show that identified uAUGs could initiate the translation indicating that the associated effect is translation-dependent. Overall, we have identified two 5'UTR ENG variations in HHT patients and shed new light on the role of upstream ORFs on ENG regulation. Our findings contribute to the amelioration of molecular diagnosis in HHT.
Identifiants
pubmed: 37848456
doi: 10.1038/s41525-023-00378-5
pii: 10.1038/s41525-023-00378-5
pmc: PMC10582052
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Subventions
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-10-LABX-0013
Informations de copyright
© 2023. Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University.
Références
Kritharis, A., Al-Samkari, H. & Kuter, D. J. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective. Haematologica 103, 1433–1443 (2018).
doi: 10.3324/haematol.2018.193003
pubmed: 29794143
pmcid: 6119150
Damjanovich, K. et al. 5’UTR mutations of ENG cause hereditary hemorrhagic telangiectasia. Orphanet J. Rare Dis. 6, 85 (2011).
doi: 10.1186/1750-1172-6-85
pubmed: 22192717
pmcid: 3277489
Faughnan, M. E. et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J. Med. Genet. 48, 73–87 (2011).
doi: 10.1136/jmg.2009.069013
pubmed: 19553198
Shovlin, C. L. et al. The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. Eur. J. Med. Genet. 65, 104370 (2022).
doi: 10.1016/j.ejmg.2021.104370
pubmed: 34737116
Faughnan, M. E. et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann. Intern. Med. 173, 989–1001 (2020).
doi: 10.7326/M20-1443
pubmed: 32894695
Al-Samkari, H. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. Blood 137, 888–895 (2021).
doi: 10.1182/blood.2020008739
pubmed: 33171488
Al-Samkari, H. et al. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica 106, 2161–2169 (2021).
doi: 10.3324/haematol.2020.261859
pubmed: 32675221
Dupuis-Girod, S. et al. European reference network for rare vascular diseases (VASCERN): when and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? Eur. J. Med. Genet. 65, 104575 (2022).
doi: 10.1016/j.ejmg.2022.104575
pubmed: 35940549
Dakeishi, M. et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum. Mutat. 19, 140–148 (2002).
doi: 10.1002/humu.10026
pubmed: 11793473
Shovlin, C. L. et al. Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. Blood 136, 1907–1918 (2020).
doi: 10.1182/blood.2019004560
pubmed: 32573726
pmcid: 7717479
Kitayama, K. et al. Mutational and clinical spectrum of Japanese patients with hereditary hemorrhagic telangiectasia. BMC Med. Genomics 14, 1–9 (2021).
doi: 10.1186/s12920-021-01139-y
Balachandar, S. et al. Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Am. J. Med. Genet. A 188, 959–964 (2022).
doi: 10.1002/ajmg.a.62584
pubmed: 34904380
Olivieri, C. et al. Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. J. Hum. Genet. 52, 820–829 (2007).
doi: 10.1007/s10038-007-0187-5
pubmed: 17786384
Komiyama, M., Ishiguro, T., Yamada, O., Morisaki, H. & Morisaki, T. Hereditary hemorrhagic telangiectasia in Japanese patients. J. Hum. Genet. 59, 37–41 (2014).
doi: 10.1038/jhg.2013.113
pubmed: 24196379
Ricard, N. et al. Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood 116, 1604–1612 (2010).
doi: 10.1182/blood-2010-03-276881
pubmed: 20501893
Mallet, C. et al. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum. Mol. Genet. 24, 1142–1154 (2015).
doi: 10.1093/hmg/ddu531
pubmed: 25312062
Prigoda, N. L. et al. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J. Med. Genet. 43, 722–728 (2006).
doi: 10.1136/jmg.2006.042606
pubmed: 16690726
pmcid: 2564570
Bayrak-Toydemir, P. et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am. J. Med. Genet. A 140, 2155–2162 (2006).
doi: 10.1002/ajmg.a.31450
pubmed: 16969873
Cole, S. G., Begbie, M. E., Wallace, G. M. F. & Shovlin, C. L. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J. Med. Genet. 42, 577–582 (2005).
doi: 10.1136/jmg.2004.028712
pubmed: 15994879
pmcid: 1736109
Wallace, G. M. & Shovlin, C. L. A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 55, 685–690 (2000).
doi: 10.1136/thorax.55.8.685
pubmed: 10899246
pmcid: 1745830
Ruiz-Llorente, L. et al. Characterization of a family mutation in the 5’ untranslated region of the endoglin gene causative of hereditary hemorrhagic telangiectasia. J. Hum. Genet. 64, 333–339 (2019).
doi: 10.1038/s10038-019-0564-x
pubmed: 30728427
pmcid: 8075931
Kim, M.-J. et al. Clinical and genetic analyses of three Korean families with hereditary hemorrhagic telangiectasia. BMC Med. Genet. 12, 130 (2011).
doi: 10.1186/1471-2350-12-130
pubmed: 21967607
pmcid: 3202234
Bossler, A. D., Richards, J., George, C., Godmilow, L. & Ganguly, A. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum. Mutat. 27, 667–675 (2006).
doi: 10.1002/humu.20342
pubmed: 16752392
Ríus, C. et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 92, 4677–4690 (1998).
doi: 10.1182/blood.V92.12.4677
pubmed: 9845534
Graulich, W., Nettelbeck, D. M., Fischer, D., Kissel, T. & Müller, R. Cell type specificity of the human endoglin promoter. Gene 227, 55–62 (1999).
doi: 10.1016/S0378-1119(98)00585-X
pubmed: 9931433
Silva, J., Fernandes, R. & Romão, L. Translational regulation by upstream open reading frames and human diseases. Adv. Exp. Med. Biol. 1157, 99–116 (2019).
doi: 10.1007/978-3-030-19966-1_5
pubmed: 31342439
Hinnebusch, A. G., Ivanov, I. P. & Sonenberg, N. Translational control by 5’-untranslated regions of eukaryotic mRNAs. Science 352, 1413–1416 (2016).
doi: 10.1126/science.aad9868
pubmed: 27313038
pmcid: 7422601
Reuter, K., Biehl, A., Koch, L. & Helms, V. PreTIS: a tool to predict non-canonical 5’ UTR translational initiation sites in human and mouse. PLoS Comput. Biol. 12, e1005170 (2016).
doi: 10.1371/journal.pcbi.1005170
pubmed: 27768687
pmcid: 5074520
Shovlin, C. L. et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am. J. Med. Genet. 91, 66–67 (2000).
doi: 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P
pubmed: 10751092
Aïssi, D. et al. MORFEE: a new tool for detecting and annotating single nucleotide variants creating premature ATG codons from VCF files. Preprint at bioRxiv https://doi.org/10.1101/2020.03.29.012054 (2020).
den Dunnen, J. T. et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum. Mutat. 37, 564–569 (2016).
doi: 10.1002/humu.22981
Labrouche-Colomer, S. et al. A novel rare c.-39C>T mutation in the PROS1 5’UTR causing PS deficiency by creating a new upstream translation initiation codon. Clin. Sci. 134, 1181–1190 (2020).
doi: 10.1042/CS20200403